Compugen (CGEN) Other Accumulated Expenses (2020 - 2021)
Compugen (CGEN) posted quarterly Other Accumulated Expenses of $4.8 million for Q4 2021, down 2.91% year-over-year from $4.9 million in Q4 2020, and down 2.91% on a QoQ basis from $4.9 million in Q4 2020.
Powered by 
Analysis
Compugen (CGEN) Other Accumulated Expenses (2020 - 2021) Analysis & Trends
Compugen has reported Other Accumulated Expenses for 2 years, with the latest figure at $4.8 million in Q4 2021.
- Other Accumulated Expenses for Q4 2021 came in at $4.8 million, down 2.91% year-over-year; the trailing twelve-month figure through Dec 2021 was $4.8 million (down 2.91% YoY), and the FY2021 annual result was $4.8 million, down 2.91% from the prior year.
- Other Accumulated Expenses eased to $4.8 million in Q4 2021, from $4.9 million in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $4.9 million in Q4 2020 and troughed at $4.8 million in Q4 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Compugen | 242.44 Mn | 156.82 Mn | -92,000.00 |